Scientific Programme – Overview

	Tuesday 16 November		Wednesday 17 November		
	ROOM A-C		ROOM A	ROOM B	ROOM C
'		08.00	Workshop 1	Workshop 2	Workshop 3
			Characterising the target for improved drug tailoring	Pharmacogenetics and pharmacogenomics in cancer	European and US initiatives for early drug development
		09.45			
				Coffee Break	
		10.15	Workshop 4	Workshop 5	Workshop 6
12.00	Lunch		Rational use of targeted therapies	Pharmacokinetics/ pharmacodynamics in cancer	New drug development in the 21st century: Do we need to break from tradition?
12.00	Lunon	40.00			tradition
13.00	Opening Ceremony	12.00	Lunch/Poster session		
13.15	spanning seconds.	14.05	Special Lecture		
	Michel Clavel lecture		Hallmarks of cancer, ten years later: evolving principles, and therapeutic targeting		
	Novel molecular imaging for early	14.45	Plenary session 2		
14.00	drug development Keynote lecture	16.15	Proffered papers		
14.45	Resistance to targeted therapy		0-# DI	l	
	Coffee Break		Coffee Break		
15.15	Plenary session 1	16.30	Plenary session 3		
17.00	Tumour stem cells: are we at the crossroads? Welcome reception	18.30	New targets and inhibitors		

Poster sessions

Cancer vaccines Molecular-targeted therapies-preclinical Monoclonal antibodies and targeted toxins/nuclides/agents Late breaking

	Thursday 18 November		Friday 19 November
	ROOM A-C		ROOM A-C
08.00	Plenary session 4	08.00	Poster viewing
	Targeting checkpoints/DNA repair in cancer	09.30	
09.45		10.30	Poster discussion
	Coffee Break		Coffee Break
10.15	Plenary session 5	11.00	Plenary session 8
	New modalities of anticancer treatment		Angiogenesis and tumour microenviroment
12.00		13.05	

Lunch/Poster session

14.05	Special Lecture	Poster sessions			
	Lessons learnt of 20 years of targeted therapies	Angiogenesis, metastasis and inhibitors Cell-cycle-interactive agents Radiation interactive agents DNA repair and inhibitors Gene therapy and antisense approaches Genetics and epigenetics			
14.45	Plenary session 6	Pharmacogenetics RNA and DNA based technologies			
16.15	Proffered papers	Bioinformatics Anthacyclines, antimetabolites, antimicrotubules, topoisomerase inhibitor Apoptosis, necrosis, autophagy			
	Coffee Break	Biomarkers Chemoprevention			
16.30	Plenary session 7	Hormonal agents Immune system			
18.30	Selected tumours as a niche for targeted therapies	Late breaking			

Poster sessions

Animal models
Clinical methodology
Combinatorial chemistry, drug screening and synthesis
Drug resistance and modifiers
Drug targets
Molecular-targeted therapies-clinical trials
Nanotechnology, drug delivery, new formulations, prodrugs
Natural products, new cytotoxics, clinical trials
Structure-activity relationship
Toxicology-side effects
Late breaking